Charles Schwab Investment Management Inc. grew its position in shares of MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 6.9% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,435,397 shares of the company's stock after buying an additional 92,726 shares during the period. Charles Schwab Investment Management Inc. owned about 0.98% of MiMedx Group worth $8,483,000 as of its most recent SEC filing.
A number of other large investors also recently bought and sold shares of the company. Isthmus Partners LLC lifted its stake in MiMedx Group by 30.4% during the second quarter. Isthmus Partners LLC now owns 393,214 shares of the company's stock worth $27,000 after purchasing an additional 91,714 shares during the last quarter. Blue Trust Inc. bought a new stake in shares of MiMedx Group in the 3rd quarter worth approximately $30,000. Point72 Asset Management L.P. bought a new stake in shares of MiMedx Group in the 2nd quarter worth approximately $40,000. Entropy Technologies LP bought a new stake in shares of MiMedx Group in the 3rd quarter worth approximately $64,000. Finally, Quest Partners LLC bought a new stake in MiMedx Group in the second quarter valued at $81,000. Institutional investors own 79.15% of the company's stock.
Wall Street Analyst Weigh In
Separately, StockNews.com cut MiMedx Group from a "strong-buy" rating to a "buy" rating in a research note on Friday, November 8th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $12.00.
Read Our Latest Stock Analysis on MiMedx Group
MiMedx Group Stock Performance
MiMedx Group stock traded down $0.29 during mid-day trading on Wednesday, hitting $9.46. 691,284 shares of the company's stock traded hands, compared to its average volume of 750,973. MiMedx Group, Inc. has a one year low of $5.47 and a one year high of $10.14. The firm has a 50 day moving average price of $7.43 and a 200 day moving average price of $6.98. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. The company has a market cap of $1.39 billion, a PE ratio of 17.73 and a beta of 1.98.
About MiMedx Group
(
Free Report)
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
Featured Articles
Before you consider MiMedx Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.
While MiMedx Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
